Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Verrica Pharmaceuticals Inc's Business Segments
Verrica Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 5
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 5 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product85.4%
- License and collaboration revenue14.6%
- License and Collaboration Revenue, Commercial Supply and Development13.9%
- License and Collaboration Revenue, Milestones0%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 4 | 85.4% |
| License and collaboration revenue | $ 1 | 14.6% |
| License and Collaboration Revenue, Commercial Supply and Development | $ 1 | 13.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Verrica Pharmaceuticals Inc dataset.
Description of Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc. is a clinical-stage medical dermatology company that focuses on developing and commercializing innovative treatments for various skin diseases. The company was founded in 2013 and is headquartered in West Chester, Pennsylvania.
Verrica Pharmaceuticals is committed to addressing unmet needs in the field of dermatology by developing novel therapies that offer patients and healthcare providers safe, effective, and convenient treatment options. Their primary focus is on developing treatments for common skin diseases, including viral infections, such as molluscum contagiosum and common warts, as well as other skin conditions.
The company's flagship product, VP-102 (cantharidin 0.7% topical solution), is a proprietary topical therapy designed to treat molluscum contagiosum, a highly contagious viral skin infection that commonly affects children. VP-102 is a non-invasive, drug-device combination product that delivers a potent active ingredient directly to the target lesion, thereby eliminating the need for injection or incision. It is currently being evaluated in clinical trials and has the potential to become the first FDA-approved treatment for molluscum contagiosum.
Verrica Pharmaceuticals is also developing VP-103, a higher concentration formulation of cantharidin, for the treatment of common warts. Common warts are caused by the human papillomavirus (HPV) and can be both physically and emotionally distressing for patients. VP-103 is designed to deliver a more potent dose of cantharidin to effectively remove warts while minimizing discomfort and scarring.
In addition to its core product pipeline, Verrica Pharmaceuticals is actively exploring other potential applications for its technology platform. The company aims to expand its therapeutic portfolio beyond viral infections and target a wider range of dermatological conditions.
Verrica Pharmaceuticals has a diverse team of experienced professionals with a strong background in pharmaceutical research, development, and commercialization. The company's leadership team includes industry veterans who have successfully brought multiple dermatology products to market.
As a clinical-stage company, Verrica Pharmaceuticals is heavily focused on conducting rigorous clinical trials to demonstrate the safety and efficacy of its products. The company has an ongoing commitment to research and development, with a focus on innovation, scientific excellence, and patient-centric solutions.
Overall, Verrica Pharmaceuticals Inc. is a cutting-edge medical dermatology company with a mission to improve the lives of patients suffering from common skin diseases. Through its innovative product pipeline and commitment to scientific advancement, the company aims to revolutionize the field of dermatology and provide patients with effective and convenient treatment options.
Verrica Pharmaceuticals is committed to addressing unmet needs in the field of dermatology by developing novel therapies that offer patients and healthcare providers safe, effective, and convenient treatment options. Their primary focus is on developing treatments for common skin diseases, including viral infections, such as molluscum contagiosum and common warts, as well as other skin conditions.
The company's flagship product, VP-102 (cantharidin 0.7% topical solution), is a proprietary topical therapy designed to treat molluscum contagiosum, a highly contagious viral skin infection that commonly affects children. VP-102 is a non-invasive, drug-device combination product that delivers a potent active ingredient directly to the target lesion, thereby eliminating the need for injection or incision. It is currently being evaluated in clinical trials and has the potential to become the first FDA-approved treatment for molluscum contagiosum.
Verrica Pharmaceuticals is also developing VP-103, a higher concentration formulation of cantharidin, for the treatment of common warts. Common warts are caused by the human papillomavirus (HPV) and can be both physically and emotionally distressing for patients. VP-103 is designed to deliver a more potent dose of cantharidin to effectively remove warts while minimizing discomfort and scarring.
In addition to its core product pipeline, Verrica Pharmaceuticals is actively exploring other potential applications for its technology platform. The company aims to expand its therapeutic portfolio beyond viral infections and target a wider range of dermatological conditions.
Verrica Pharmaceuticals has a diverse team of experienced professionals with a strong background in pharmaceutical research, development, and commercialization. The company's leadership team includes industry veterans who have successfully brought multiple dermatology products to market.
As a clinical-stage company, Verrica Pharmaceuticals is heavily focused on conducting rigorous clinical trials to demonstrate the safety and efficacy of its products. The company has an ongoing commitment to research and development, with a focus on innovation, scientific excellence, and patient-centric solutions.
Overall, Verrica Pharmaceuticals Inc. is a cutting-edge medical dermatology company with a mission to improve the lives of patients suffering from common skin diseases. Through its innovative product pipeline and commitment to scientific advancement, the company aims to revolutionize the field of dermatology and provide patients with effective and convenient treatment options.
Verrica Pharmaceuticals Inc. is a clinical-stage dermatology company focused on developing and commercializing innovative therapies for skin diseases. Their primary focus is on therapies that address significant unmet medical needs in dermatology.
Segments
Verrica operates primarily in the pharmaceutical segment, specifically within dermatology. Their emphasis is on therapeutic solutions targeting skin disorders, including warts, acne, and other skin conditions. This segment is characterized by a strong emphasis on research and development capabilities, clinical trials, and regulatory engagement to bring products to market.
Dermatology Focus
The company concentrates on the following areas within dermatology:
1. Clinical Development: This includes the design and execution of clinical trials to evaluate the efficacy and safety of their drug candidates.
2. Regulatory Affairs: Engaging with regulatory bodies to ensure compliance and facilitate the approval process for their products.
3. Commercialization: Once products are approved, Verrica focuses on launching and marketing them to healthcare providers and patients.
Products
Verrica Pharmaceuticals has developed a portfolio of product candidates targeting various dermatological conditions. Their most notable products include:
1. VP-102 (Cantharidin Topical Solution): This is Verricas lead product candidate. VP-102 is designed for the treatment of common warts, utilizing cantharidin to create a blistering effect that facilitates the removal of warts. The product is in late-stage clinical development aimed at providing a non-invasive, easy-to-use treatment option suitable for both pediatric and adult populations.
2. VP-201: While details about this product candidate may vary, it is generally positioned to address additional dermatological conditions. Ongoing research may involve exploring various formulations or delivery mechanisms to enhance therapeutic outcomes.
3. Pipeline Products: Verrica continuously works on expanding its pipeline through the development of additional candidates that may target other skin conditions and disorders, providing a broader spectrum of treatment options in the field of dermatology.
Services
Verrica Pharmaceuticals also encompasses several services within its operational framework:
1. Clinical Research Services: Through its clinical trial services, Verrica collaborates with various clinical research organizations to conduct studies required for product development, focusing on efficacy, safety, and tolerability.
2. Regulatory Compliance and Support: The company provides support services to navigate the complexities of regulatory environments, ensuring that their products meet all necessary health and safety standards required by agencies such as the U.S. Food and Drug Administration (FDA).
3. Patient and Physician Education: Verrica engages in educational initiatives aimed at both healthcare providers and patients to increase awareness about their treatment options and to promote better outcomes through informed healthcare decision-making.
4. Market Access Strategy: The company implements strategies to facilitate access to its products within the healthcare market, working to establish relationships with payers, healthcare systems, and providers to ensure that patients can gain access to their innovative therapies.
5. Partnerships and Collaborations: Verrica often seeks strategic partnerships with other pharmaceutical and biotechnology firms to enhance their research capabilities, increase market reach, and improve patient outcomes.
Conclusion
Verrica Pharmaceuticals is focused on the advancement of effective and innovative dermatological therapies, with a commitment to addressing significant unmet needs in skin disease management. By developing products like VP-102 and maintaining an expansive pipeline, along with offering various services, the company seeks not only to enhance the quality of care for patients but also to position itself as a leader in dermatological solutions.
Segments
Verrica operates primarily in the pharmaceutical segment, specifically within dermatology. Their emphasis is on therapeutic solutions targeting skin disorders, including warts, acne, and other skin conditions. This segment is characterized by a strong emphasis on research and development capabilities, clinical trials, and regulatory engagement to bring products to market.
Dermatology Focus
The company concentrates on the following areas within dermatology:
1. Clinical Development: This includes the design and execution of clinical trials to evaluate the efficacy and safety of their drug candidates.
2. Regulatory Affairs: Engaging with regulatory bodies to ensure compliance and facilitate the approval process for their products.
3. Commercialization: Once products are approved, Verrica focuses on launching and marketing them to healthcare providers and patients.
Products
Verrica Pharmaceuticals has developed a portfolio of product candidates targeting various dermatological conditions. Their most notable products include:
1. VP-102 (Cantharidin Topical Solution): This is Verricas lead product candidate. VP-102 is designed for the treatment of common warts, utilizing cantharidin to create a blistering effect that facilitates the removal of warts. The product is in late-stage clinical development aimed at providing a non-invasive, easy-to-use treatment option suitable for both pediatric and adult populations.
2. VP-201: While details about this product candidate may vary, it is generally positioned to address additional dermatological conditions. Ongoing research may involve exploring various formulations or delivery mechanisms to enhance therapeutic outcomes.
3. Pipeline Products: Verrica continuously works on expanding its pipeline through the development of additional candidates that may target other skin conditions and disorders, providing a broader spectrum of treatment options in the field of dermatology.
Services
Verrica Pharmaceuticals also encompasses several services within its operational framework:
1. Clinical Research Services: Through its clinical trial services, Verrica collaborates with various clinical research organizations to conduct studies required for product development, focusing on efficacy, safety, and tolerability.
2. Regulatory Compliance and Support: The company provides support services to navigate the complexities of regulatory environments, ensuring that their products meet all necessary health and safety standards required by agencies such as the U.S. Food and Drug Administration (FDA).
3. Patient and Physician Education: Verrica engages in educational initiatives aimed at both healthcare providers and patients to increase awareness about their treatment options and to promote better outcomes through informed healthcare decision-making.
4. Market Access Strategy: The company implements strategies to facilitate access to its products within the healthcare market, working to establish relationships with payers, healthcare systems, and providers to ensure that patients can gain access to their innovative therapies.
5. Partnerships and Collaborations: Verrica often seeks strategic partnerships with other pharmaceutical and biotechnology firms to enhance their research capabilities, increase market reach, and improve patient outcomes.
Conclusion
Verrica Pharmaceuticals is focused on the advancement of effective and innovative dermatological therapies, with a commitment to addressing significant unmet needs in skin disease management. By developing products like VP-102 and maintaining an expansive pipeline, along with offering various services, the company seeks not only to enhance the quality of care for patients but also to position itself as a leader in dermatological solutions.